Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.
Also called NCT03506815
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 105 participants
- Sponsor
- Registry
-
NCT03506815
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT03506815. Randomized; no masking; primary purpose prevention. Start 2019-03-15 (actual); primary completion 2020-05-14 (actual). Results posted on 2024-07-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
- Acronym
- TRIM-Line
- Condition
- Upper Extremity Deep Vein Thrombosis
- Condition
- Central Venous Catheter Thrombosis
- Condition
- Cancer
- Intervention (Drug)
- Rivaroxaban 10 MG
- Lead sponsor
- Ottawa Hospital Research Institute
- Collaborator
- Queen Elizabeth II Health Sciences Centre
- Collaborator
- University of Alberta
- Collaborator
- Hamilton Health Sciences Corporation
Record details
- Record id
cardio:ct-nct03506815- Content hash
b9ee0da56bd8d0763698d55b78ff05602e729cb2a4a97fcbfa736c655985e7df